The AMBITION study: Superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA)

被引：0
|
作者：
Jones, G. [1 ]
Gu, J. R. [2 ]
Lowenstein, M. [3 ]
Calvo, A.
Gomez-Reino, J. J. [4 ,5 ]
Siri, D. [6 ]
Tomsic, M. [7 ]
Blackburn, R.
Woodworth, T.
Sebba, A. [9 ]
Genovese, M. [8 ]
机构：
[1] Univ Tasmania, Hobart, Tas, Australia
[2] Hosp Sun Yat Sen Univ, Guangzhou, Peoples R China
[3] Ctr Arthritis, Palm Harbor, FL USA
[4] Univ Peruana Cayetano Heredia, San Felipe Clin, Lima, Peru
[5] Univ Santiago de Compostela, Santiago De Compostela, Spain
[6] Inst CAICI, Rosario, Argentina
[7] Univ Med Ctr, Ljubljana, Slovenia
[8] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[9] Arthritis Res Florida, Palm Harbor, FL USA
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S618 / S618
页数：1
相关论文
共 50 条
  • [21] ASSOCIATION OF METHOTREXATE (MTX) AND STEROIDS IN THE TREATMENT OF RHEUMATOID-ARTHRITIS (RA) PATIENTS
    BOLOGNA, C
    VIU, P
    JORGENSEN, C
    SANY, J
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 1280 - 1280
  • [22] IMMUNOREGULATORY EFFECTS OF METHOTREXATE (MTX) IN RHEUMATOID-ARTHRITIS (RA)
    OLSEN, N
    MURRAY, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (02) : 169 - 169
  • [23] TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS (RA) WITH METHOTREXATE (MTX)
    LOMBARDOZZI, J
    CLINICAL RESEARCH, 1984, 32 (02): : A664 - A664
  • [24] TOCILIZUMAB (TCZ) AS COMBINATION THERAPY AND AS MONOTHERAPY VS METHOTREXATE (MTX) IN MTX-NAIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: PATIENT-REPORTED OUTCOMES (PROS) FROM A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Burmester, G.
    Blanco, R.
    Keiserman, M.
    Rigby, W.
    van Vollenhoven, R. F.
    Dimonaco, S. M.
    Grzeschik, S. M.
    Mitchell, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 672 - 672
  • [25] Patients achieve significant improvement in rheumatoid arthritis (RA) outcomes with tociluzumab (TCZ) regardless of prior inadequate response (IR) to TNF antagonists
    Emery, P.
    Keystone, E.
    Tony, H. P.
    Law, A.
    Woodworth, T.
    Kremer, J.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S533 - S533
  • [26] Tociluzumab (TCZ) improves quality of life (QOL) in patients with rheumatoid arthritis (RA) who had inadequate response (IR) to TNF antagonists
    Kremer, J.
    Pope, J.
    Ton, H. P.
    Burmester, G. R.
    Hall, S.
    Euller-Ziegler, L.
    Woodworth, T.
    Alecock, E.
    Emery, P.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S533 - S534
  • [27] Tociluzumab (TCZ) rapidly and significantly improves outcomes in patients with rheumatoid arthritis (RA) who have inadequate response (IR) to TNF antagonists
    Emery, P.
    Keystone, E.
    Tony, H. P.
    Cantagrel, A.
    van Vollenhoven, R.
    Sanchez, A.
    Alecock, E.
    Lee, J.
    Kremer, J.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S617 - S618
  • [28] Effects of renal insufficiency on pharmacokinetics of methotrexate (MTX) in rheumatoid arthritis (RA) patients.
    Combe, B
    Kinowski, JM
    Bologna, C
    Sany, J
    Bressolle, F
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 382 - 382
  • [29] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
  • [30] Folic acid alters methotrexate (MTX) disposition in rheumatoid arthritis (RA) patients.
    Combe, B
    Kinowski, JM
    Pouly, B
    Sany, J
    Bressolle, F
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S76 - S76
12345